Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 11Mesothelioma, Malignant 8Solid Tumor 6Advanced Solid Tumor 6Mesothelioma 3Melanoma 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumors 3Treatment-Refractory Solid Tumors 2Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Merkel Cell 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Solid Tumour 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Select Advanced Solid Tumors 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Solid Tumors 1Locally Advanced Solid Tumor 1Kidney Neoplasms 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Rare Malignant Solid Neoplasm × atezolizumab × Other solid neoplasm × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡